References
- American Lung AssociationChronic Obstructive Pulmonary disease (COPD) Fact SheetWashington, DCAmerican Lung Association2009 Available at: www.lungusa.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html#note_08Accessed 2010 Nov 12
- National Heart, Lung and Blood InstituteMorbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung, and Blood DiseasesBethesda, MDU.S. Department of Health and Human Services2007
- CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paperEur Respir J20042393294615219010
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for diagnosis, management and prevention of COPDGig Harbor, WAMedical Communications Resources, Inc200912
- AkazawaMHayflingerDCStanfordRHBlanchetteCMEconomic assessment of initial maintenance therapy for chronic obstructive pulmonary diseaseAm J Manag Care20081443844818611095
- AnzuetoAMcLaughlinTStanfordRHInitial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary diseaseCOPD2004120521417136988
- BlanchetteCMAkazawaMDalalASimoni-WastilaLRisk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 μg/salmeterol 50 μg compared with ipratropium for chronic obstructive pulmonary disease in older adultsAm J Geriatr Pharmacother2008613814618775388
- DalalAAPetersenHSimoni-WastilaLBlanchetteCMHealthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPDJ Med Econ20091233934719827993
- DeleaTEHagiwaraMDalalAAStanfordRHBlanchetteCMHealthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapiesCurr Med Res Opin20092511319210134
- RascatiKLStanfordRHBorkerRA comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combinationClin Ther20052734635415878389
- RascatiKLAkazawaMJohnsrudMStanfordRHBlanchetteCMComparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimenClin Ther2007291203121317692734
- OostenbrinkJBRutten-van MölkenMPAlMJvan NoordJAVinckenWOne-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary diseaseEur Respir J20042324124914979498
- WedzichaJACalverleyPMASeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
- TukeyJWExploratory Data Analysis1st edReading, MAAddison- Wesley Publishing Company1977
- VinckenWvan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 year’s treatment with tiotropiumEur Respir J20021920921611871363
- DalalAABlanchetteCMRobertsMHPetersenHVMapelDWHealthcare utilization and direct medical costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus tiotropium in elderly, Medicare-eligible patients with COPDJ Med Econ2010920 [Epub ahead of print]
- MapelDWMcMillanGPFrostFJPredicting the costs of managing patients with chronic obstructive pulmonary diseaseRespir Med2005991325133316140232
- WelteTOptimising treatment for COPD – new strategies for combination therapyInt J Clin Pract2009631136114919624783